Campath

(Alemtuzumab)

ApprovedMonoclonal antibody

Alemtuzumab is used to treat certain types of blood cancers (like chronic lymphocytic leukemia) and relapsing-remitting multiple sclerosis by targeting and destroying specific immune cells in the body.[2] Campath is currently approved and in use across 27 indications[4].[1]

Campath is one of 322 small molecule programs targeting Sickle Cell Disease. It is currently in Approved.

Indications

206

Total Trials

Active Trials

321

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Sickle Cell DiseaseActive, not recruiting

HemoglobinopathiesRecruiting

Non-Malignant DisordersTerminated

Stem Cell TransplantCompleted

Hematopoietic and Lymphoid Cell NeoplasmActive, not recruiting

Dyskeratosis CongenitaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

CD40L-Hyperigm SyndromeRecruiting

Chronic Granulomatous Disease TransplantActive, not recruiting

Sickle Cell AnemiaRecruiting

Sickle Cell DiseasePhase 3

Active, not recruiting

HemoglobinopathiesPhase 2

Recruiting

Non-Malignant DisordersPhase 2

Terminated

Stem Cell TransplantPhase 2

Completed

Hematopoietic and Lymphoid Cell NeoplasmPreclinical

Active, not recruiting

Dyskeratosis CongenitaPreclinical

Active, not recruiting

Renal Cell CarcinomaPreclinical

Active, not recruiting

CD40L-Hyperigm SyndromePreclinical

Recruiting

Chronic Granulomatous Disease TransplantPreclinical

Active, not recruiting

Sickle Cell AnemiaPreclinical

Recruiting

Showing 10 of 27 indications

Competition

Competitive Landscape

98 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Approved

13 2

Ritalin

Novartis

Phase 3

2 3

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 4

Toradol

JJavelin Pharmaceuticals

Phase 3

2 5

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

1 6

Fludara

Sanofi

Phase 2

9 7

Cellcept

Roche

Phase 2

6 8

PIASKY

Roche

Phase 3

2 9

Tepadina

Jazz Pharmaceuticals

Phase 2

4 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hematopoietic Stem Cell Transplantation

NCT04018937

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Q1 2027

Phase 1/2Active, not recruiting

Sickle Cell Disease

NCT05357482

Q2 2027

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT01361711

Q4 2027

Phase 2Recruiting

Non-Malignant Disorders

NCT01962415

Phase 2Active, not recruiting

Acute Lymphoblastic Leukaemia

NCT03821610

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia31 trials

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00276809·30 enrolled

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Suspended·SShanghai Zhangjiang Biotechnology Limited Company·Phase 2·NCT01982175·120 enrolled

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00871546·8 enrolled

Show 28 more trials

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00098670·102 enrolled

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Completed·MMayo Clinic·Phase 2·NCT00436904·30 enrolled

Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00143065·8 enrolled

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT00951457·20 enrolled

Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Completed·GGerman CLL Study Group·Phase 2·NCT00274976

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Terminated· Sanofi logo

Sanofi··NCT00836043·6 enrolled

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MMayo Clinic·Phase 1/2·NCT00935792·28 enrolled

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00278213·17 enrolled

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00669318·41 enrolled

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed· Sanofi logo

Sanofi·Phase 1·NCT00923182·6 enrolled

Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia

Unknown status·TTawam Hospital·N/A·NCT00336206·60 enrolled

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004857·86 enrolled

Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

Completed·KKarolinska University Hospital·Phase 2·NCT00162851·20 enrolled

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01013961·31 enrolled

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006390

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Completed·MMayo Clinic·Phase 1/2·NCT01269385·22 enrolled

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting·NNorthwestern University·Phase 2·NCT01361711·53 enrolled

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·SSteven E. Coutre·Phase 2·NCT00230282·25 enrolled

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Terminated·—·Phase 1·NCT00947388·9 enrolled

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

Completed· Bayer logo

Bayer·Phase 2·NCT00086775

Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

Completed·—·N/A·NCT00021151·2 enrolled

Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia

Unknown status·—·Phase 2·NCT00337519·82 enrolled

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00525603·60 enrolled

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission

Completed·—·Phase 2·NCT00458523·54 enrolled

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Completed· Sanofi logo

Sanofi·Phase 2·NCT00328198·86 enrolled

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Completed·MMayo Clinic·Phase 2·NCT00562328·33 enrolled

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01082939·80 enrolled

Lymphoma14 trials

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

Unknown status·—·Phase 1/2·NCT00363090·84 enrolled

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 1·NCT00562068·30 enrolled

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00069238·31 enrolled

Show 11 more trials

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas

Completed·OOntario Clinical Oncology Group (OCOG)·Phase 1/2·NCT00453427·20 enrolled

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT02059239·34 enrolled

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00907036·49 enrolled

Cyclophosphamide and Alemtuzumab In Lymphoma

Terminated·—·Phase 1·NCT03132584·3 enrolled

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

Completed·UUniversity of Göttingen·Phase 2·NCT01806337·41 enrolled

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

Unknown status·UUniversity of Göttingen·Phase 3·NCT00725231·274 enrolled

The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)

Completed·KKing Chulalongkorn Memorial Hospital·Phase 2·NCT00930605·16 enrolled

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00908180·47 enrolled

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00323323·24 enrolled

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT00051701·61 enrolled

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01625351·23 enrolled

Multiple Sclerosis12 trials

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Terminated·—·Phase 2·NCT01679041·1 enrolled

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Completed· Sanofi logo

Sanofi·Phase 3·NCT00930553·1,314 enrolled

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Completed· Sanofi logo

Sanofi·Phase 3·NCT00548405·840 enrolled

Show 9 more trials

Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

Completed·MMaritime Neurology··NCT04633967·30 enrolled

The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients

Unknown status·GGlostrup University Hospital, Copenhagen··NCT03193086·35 enrolled

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT03135249·9 enrolled

Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

Completed·UUniversity of British Columbia··NCT06705608·4,000 enrolled

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

Unknown status·CCentral Texas Neurology Consultants·Phase 3·NCT01333358·30 enrolled

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis

Terminated·—·Phase 1/2·NCT01712945·40 enrolled

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

Completed·UUniversity of Chicago·Phase 4·NCT01395316·8 enrolled

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Completed· Sanofi logo

Sanofi·Phase 3·NCT00530348·581 enrolled

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

Terminated·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2·NCT04971005·1 enrolled

Sickle Cell Disease10 trials

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Terminated·WWashington University School of Medicine·Phase 1·NCT02678143·1 enrolled

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

Recruiting·—·Phase 2·NCT06358638·12 enrolled

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Active, not recruiting·—·Phase 2·NCT00408447·53 enrolled

Show 7 more trials

Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Recruiting·UUniversity of Calgary·Phase 2·NCT03214354·12 enrolled

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Stem Cell Transplant in Patients With Severe Sickle Cell Disease

Terminated·KKathleen Dorritie·Phase 1·NCT03421756·1 enrolled

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT03077542·57 enrolled

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT05357482·40 enrolled

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT07599176·90 enrolled

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant Failure

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02105766·56 enrolled

Stem Cell Transplant9 trials

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT00818961·36 enrolled

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Completed·WWeill Medical College of Cornell University·Phase 2·NCT02497404·40 enrolled

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Withdrawn·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00085449

Show 6 more trials

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00555048·1 enrolled

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027560·51 enrolled

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting·DDiane George·Phase 1/2·NCT02061800·14 enrolled

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·YYale University·Phase 1·NCT00104975·20 enrolled

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00118352·12 enrolled

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Completed·UUniversity of California, San Francisco·Phase 2·NCT00301834·35 enrolled

90 more indications

Kidney Transplant6 trials

Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

Terminated·UUniversity of Minnesota·Phase 4·NCT00177138·9 enrolled

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

Completed·UUniversity of Miami·Phase 1/2·NCT00183248·9 enrolled

Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection

Unknown status·PPirogov Russian National Research Medical University·Phase 1/2·NCT01446484·30 enrolled

Show 3 more trials

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00240994·35 enrolled

Simultaneous Pancreas-kidney Transplantation With Campath Protocol

Completed·—·Phase 3·NCT00316810·30 enrolled

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

Completed·UUniversity of Wisconsin, Madison·Phase 1/2·NCT00078559·10 enrolled

Acute Lymphoblastic Leukemia5 trials

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·UUniversity of California, San Diego·Phase 1/2·NCT00983528·6 enrolled

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00061945·302 enrolled

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00262925·12 enrolled

Show 2 more trials

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089349·25 enrolled

Allogeneic Stem Cell Transplantation4 trials

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01518153·16 enrolled

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Completed·—·Phase 2/3·NCT01019876·38 enrolled

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Completed·—·Phase 2·NCT00153985·2 enrolled

Show 1 more trial

Non-Myeloablative Allogeneic Stem Cell Transplantation

Completed·MM.D. Anderson Cancer Center·N/A·NCT00525876·49 enrolled

Bone Marrow Transplantation4 trials

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Recruiting·PPaul Szabolcs·Phase 1/2·NCT03500731·8 enrolled

Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)

Unknown status·HHadassah Medical Organization·N/A·NCT02529839·20 enrolled

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Completed·MMedical College of Wisconsin·Phase 2·NCT02766465·138 enrolled

Show 1 more trial

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Active, not recruiting·—·Phase 2·NCT01659606·40 enrolled

Severe Aplastic Anemia3 trials

Alemtuzumab to Treat Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00195624·47 enrolled

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00260689·136 enrolled

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

Unknown status·FFederico II University·Phase 2·NCT00895739·50 enrolled

Leukemia3 trials

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00345345·29 enrolled

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

Completed· Sanofi logo

Sanofi·Phase 3·NCT00046683·284 enrolled

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02689453·11 enrolled

Chronic Granulomatous Disease3 trials

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled

Completed·—·Phase 2·NCT00578643·15 enrolled

Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03910452·4 enrolled

Islet Transplantation2 trials

Islet Transplantation Using Campath-1H and Infliximab Induction

Completed·UUniversity of Alberta·Phase 2·NCT00175266·12 enrolled

Alemtuzumab Induction in Islet Transplantation

Completed·UUniversity of Alberta·Phase 2·NCT00175253·12 enrolled

Histiocytosis2 trials

Treatment of Familiar Lymphohistiocytosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT02472054·29 enrolled

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02385110·18 enrolled

Phase II2 trials

SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD

Terminated·—·Phase 2·NCT02013375·2 enrolled

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

Completed·NNorthwestern University·Phase 2·NCT00858117·30 enrolled

Non-malignant Disorders2 trials

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Recruiting·PPaul Szabolcs·Phase 2·NCT01962415·100 enrolled

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Terminated·—·Phase 1/2·NCT00801931·1 enrolled

Hemoglobinopathies2 trials

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Completed·NNorthwell Health·Phase 1/2·NCT02435901·29 enrolled

Allo HSCT for High Risk Hemoglobinopathies

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06872333·62 enrolled

CLL2 trials

Alemtuzumab + Rituximab Consolidation in CLL

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00771602·1 enrolled

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Terminated·—·Phase 2·NCT01465334·30 enrolled

Mycosis Fungoides2 trials

Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

Completed·NNorthwestern University·Phase 2·NCT00057967·37 enrolled

Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

Unknown status·LLatin American Cooperative Onco-Haematology Group - Peru·Phase 2·NCT00157274·20 enrolled

Anemia2 trials

Haploidentical PBMC Transplant for Severe Congenital Anemias

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00977691·23 enrolled

Stem Cell Transplantation for Sickle Cell Anemia

Completed·HHackensack Meridian Health·Phase 3·NCT01877837·30 enrolled

Myelodysplastic Syndrome2 trials

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00217594·40 enrolled

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01191749·7 enrolled

Methylprednisolone2 trials

Campath-1H + FK506 and Methylprednisolone for GVHD

Completed·—·Phase 2·NCT00109993·34 enrolled

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00292760

Allogeneic Hematopoietic Cell Transplant2 trials

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Recruiting·—·Phase 2·NCT05501756·60 enrolled

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Terminated·UUniversity of California, San Francisco·Phase 2·NCT01596699·16 enrolled

Hematological Malignancies2 trials

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00566696·73 enrolled

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00040846·60 enrolled

AIN1 trial

Autologous Transplant Targeted Against Crohn's

Withdrawn·NNorthwestern University·Phase 2·NCT04154735

Tolerance1 trial

Belatacept Post Depletional Repopulation to Facilitate Tolerance

Completed·—·Phase 2·NCT00565773·40 enrolled

Pregnancy1 trial

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting· Biogen logo

Biogen··NCT05688436·1,178 enrolled

Suicide1 trial

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01875237·3 enrolled

Relapse1 trial

Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Completed·—·Phase 1·NCT00330252·29 enrolled

Immunosuppression1 trial

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

Terminated·NNorthwestern University·Phase 4·NCT00166712·40 enrolled

Efficacy1 trial

A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT00565981·10 enrolled

Conditioning1 trial

Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

Terminated·CCABYC·Phase 2·NCT00781781·34 enrolled

Acute Graft Versus Host Disease1 trial

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00410657·53 enrolled

T-Cell Neoplasm1 trial

Alemtuzumab and Pentostatin In T-cell Neoplasms

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00453193·26 enrolled

T Cell1 trial

Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?

Unknown status·—··NCT05905770·20 enrolled

Risk Stratification1 trial

Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

Unknown status·UUniversity Hospital Muenster··NCT04082260·150 enrolled

Relapsing-Remitting Multiple Sclerosis1 trial

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Completed· Sanofi logo

Sanofi·Phase 2·NCT00050778·334 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)

Withdrawn·JJohns Hopkins University·Phase 4·NCT01757574

Inclusion Body Myositis1 trial

Alemtuzumab to Treat Sporadic Inclusion Body Myositis

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00079768·20 enrolled

T-cell acute lymphoblastic leukemia1 trial

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

Completed·GGoethe University·Phase 2·NCT00199030·8 enrolled

Residual Disease1 trial

Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy

Unknown status·CChronic Lymphocytic Leukemia Research Consortium·Phase 2·NCT00800943·31 enrolled

Chronic GVHD1 trial

Campath in Chronic GVHD

Completed·—·Phase 1·NCT00495755·13 enrolled

Hodgkin's Disease1 trial

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00129753

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Stem Cell Transplantation1 trial

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00520130·92 enrolled

Type 1 Diabetes1 trial

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Completed·UUniversity of Alberta·Phase 1/2·NCT03182426·22 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias

Terminated·PPhramongkutklao College of Medicine and Hospital·Phase 2·NCT00472433·30 enrolled

Myelodysplastic Syndromes1 trial

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Cytomegalovirus Infection1 trial

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Unknown status·UUniversity Hospital Birmingham·Phase 2·NCT00986557·78 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Liver Transplant1 trial

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00105235·27 enrolled

Mantle Cell Lymphoma1 trial

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00720447·25 enrolled

Treatment1 trial

Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

Completed·UUniversity of Aarhus··NCT03806387·17 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Terminated·UUniversity of Arizona·Phase 2·NCT00698685·14 enrolled

Graft Vs Host Disease1 trial

Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00775632·78 enrolled

Immunodeficiency1 trial

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00553098·29 enrolled

ESS1 trial

Neurofilaments for NEDA Assessing in MS

Terminated·QQueen Mary University of London··NCT03250169·21 enrolled

Renal Transplant Recipients1 trial

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Completed· Astellas logo

Astellas·Phase 4·NCT00113269·501 enrolled

Macroglobulinemia1 trial

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT00081068

Recessive Dystrophic Epidermolysis Bullosa1 trial

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Terminated·—·Phase 1·NCT00881556·3 enrolled

Primary Peritoneal Cancer1 trial

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT00637390·3 enrolled

T Cells1 trial

Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

Terminated·NNorthwestern University·Phase 4·NCT01213329·52 enrolled

Nephropathy1 trial

Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy

Completed·UUniversity of Oxford·Phase 2/3·NCT01120028·852 enrolled

Acute Lymphoblastic Leukaemia1 trial

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT03821610·242 enrolled

High Risk1 trial

HSCT for High Risk Inherited Inborn Errors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00383448·38 enrolled

Neurodegeneration1 trial

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

Completed·UUniversity Hospital Muenster·Phase 4·NCT02419378·15 enrolled

Prolymphocytic Leukemia1 trial

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Completed·GGerman CLL Study Group·Phase 2·NCT01186640·16 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Active, not recruiting·HHaukeland University Hospital·Phase 3·NCT03477500·100 enrolled

Intestinal Transplantation1 trial

Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation

Completed·UUniversity of Pittsburgh·Phase 2·NCT01208337·23 enrolled

TED1 trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled

Renal Cell Carcinoma1 trial

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Completed·—·N/A·NCT00073879

Refractory1 trial

Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects

Unknown status·SSamuel Forrester Hunter, MD, PhD·Phase 1·NCT01624714·60 enrolled

Bone Marrow Failure1 trial

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04232085·27 enrolled

T-Cell Prolymphocytic Leukemia1 trial

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03989466·15 enrolled

Transplantation1 trial

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

Completed·WWake Forest University Health Sciences·Phase 4·NCT00331162·222 enrolled

Autologous Stem Cell Transplantation1 trial

Autologous Stem Cell Transplantation for Crohn's Disease

Recruiting·PPaul Szabolcs·Phase 1/2·NCT00692939·20 enrolled

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00074282·102 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Active, not recruiting·EEmory University·Phase 2·NCT04018937·43 enrolled

Langerhans Cell Histiocytosis1 trial

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00618540·1 enrolled

Graft Rejection1 trial

Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection

Completed·—·Phase 3·NCT00147381·197 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00061048·29 enrolled

Vasculitis1 trial

Alemtuzumab for ANCA Associated Refractory Vasculitis

Unknown status·—·Phase 4·NCT01405807·24 enrolled

Renal Transplantation1 trial

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01436305·19 enrolled

Dexamethasone1 trial

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

Completed·UUniversity of Ulm·Phase 2·NCT01392079·135 enrolled

Randomized1 trial

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Completed·UUniversity of Miami·Phase 4·NCT01172418·200 enrolled

Newly Diagnosed1 trial

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Terminated·MMahidol University·Phase 2·NCT00441025·4 enrolled

Chronic Granulomatous Disease Transplant1 trial

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT02629120·45 enrolled

Hemolytic Anemia1 trial

Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT00061568·130 enrolled

Lymphoproliferative Disorders1 trial

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04339777·66 enrolled

Systemic Sclerosis1 trial

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Recruiting·PPaul Szabolcs·Phase 2·NCT03630211·8 enrolled

Sickle Cell Anemia1 trial

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Recruiting·PPaul Szabolcs·Preclinical·NCT03653338·5 enrolled

Chronic Granulomatous Disease (CGD)1 trial

Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT06325709·15 enrolled

Unspecified2 trials

Precision Dosing of Alemtuzumab

Completed·—·N/A·NCT03302754·12 enrolled

ADAs to Alemtuzumab

Completed·QQueen Mary University of London··NCT06310343·15 enrolled

Regulatory

FDA Approval Timeline[5]

May 7, 2001

CAMPATH

BLA BLA103948

Sources

References

[1]
ClinicalTrials.gov — 206 trial records for Alemtuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Campath drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Alemtuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Alemtuzumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA103948). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Genzyme, a Sanofi Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CAMPATH-1 Antigen Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: GGenzyme, a Sanofi Company